PDCD1 and cancer: Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) have made significant breakthroughs in cancer treatment.